Effect of Gemcabene on the Pharmacokinetics of Simvastatin in Healthy Volunteers
NCT ID: NCT02587390
Last Updated: 2020-04-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
20 participants
INTERVENTIONAL
2000-05-31
2000-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Pharmacokinetics and Pharmacodynamics Study of Gemcabene in Healthy Volunteers
NCT02587364
Pharmacokinetics of Simvastatin and Its Metabolite Simvastatin Acid With and Without Concomitant Administration of Telmisartan in Healthy Subjects
NCT02187536
Effect of Repeated Oral Doses of Avacopan on the Pharmacokinetics (PK) of a Single Dose of Simvastatin
NCT06207682
Influence of Hepatic Impairment on Pharmacokinetic (PK) and Pharmacodynamic (PD) of Gemigliptin PK and PD After Multiple Oral Doses in Healthy White Volunteers
NCT02004587
A Pharmacokinetic and Drug Interaction Study of JNJ-26489112 in Healthy Volunteers
NCT01147887
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
CROSSOVER
BASIC_SCIENCE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Gemcabene 900 mg
Gemcabene 900 mg
Gemcabene 900 mg
3x300 mg Gemcabene tablets orally once daily (QD) for 15 days
Simvastatin 80 mg
2x40 mg Simvastatin tablets orally once daily (QD) for 15 days
Simvastatin 80 mg
Simvastatin 80 mg
Simvastatin 80 mg
2x40 mg Simvastatin tablets orally once daily (QD) for 15 days
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Gemcabene 900 mg
3x300 mg Gemcabene tablets orally once daily (QD) for 15 days
Simvastatin 80 mg
2x40 mg Simvastatin tablets orally once daily (QD) for 15 days
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* \>18 years of age
* Body weight 45 kg or greater
Exclusion Criteria
* History of significant adverse reaction to any fibrate lipid-lowering agent or HMG-CoA reductase inhibitor
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
NeuroBo Pharmaceuticals Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
1027-008
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.